Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 8INDUSTRY 4NIH 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

canakinumab 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Juvenile × Clear all
NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Novartis

Phase 3 Completed
31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

NCT03769558 2020-03-20

A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

Bristol-Myers Squibb

Completed
264 enrolled

Arthritis, Juvenile

NCT03780959 2019-08-02

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Amgen

Phase 2/3 Completed
69 enrolled 11 charts

Arthritis, Juvenile

NCT01206907 2012-08-17

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Endo Pharmaceuticals

Phase 3 Withdrawn
Classical hematology

Anemia, Sickle Cell, Arthritis, Juvenile, Neoplasms, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡